
Stanford



Kensuke Kayamori

Postdoctoral Scholar, Stem Cell Biology and Regenerative Medicine

Publications

PUBLICATIONS

- **Chromatin accessibility in stem cells unveils progressive transcriptional alterations in myelodysplastic syndrome** *NATURE COMMUNICATIONS*

  Oshima, M., Takayama, N., Nakajima-Takagi, Y., Shinoda, D., Itokawa, N., Kurosawa, S., Kaito, S., Kamiya, T., Yamada, Y., Andoh, S., Kayamori, K., Paul, S., Kanashiro, et al

  2025; 16 (1): 10726

- **DNMT3A R882H Is Not Required for Disease Maintenance in Primary Human AML, but Is Associated With Increased Leukemia Stem Cell Frequency.** *Cancer discovery*

  Köhnke, T., Karigane, D., Hilgart, E., Fan, A. C., Kayamori, K., Miyauchi, M., Collins, C. T., Suchy, F. P., Rangavajhula, A., Feng, Y., Nakauchi, Y., Martinez-Montes, E., Fowler, et al

  2025

- **FLT3 ligand facilitates long-term ex vivo expansion of human hematopoietic stem cells by maintaining lymphoid reconstitution potential**

  Miyauchi, M., Banuelos, A., Mack, P., Suchy, F., Tan, T., Charlesworth, C., Homma, S., Zhang, J., Kayamori, K., Yilmaz, L., Bhadury, J., Karigane, D., Nakauchi, et al

  ELSEVIER.2025: 4931-4932

- **Inhibition of DOCK1 prevents the clonal expansion of high-risk TP53-mutant clonal hematopoiesis induced by genotoxic stressors**

  Feng, Y., Koehnke, T., Patrick, B., Benard, B., Kayamori, K., Heaton, E., Collins, C., Chavez, J., Zhang, T., Gentles, A., Majeti, R.

  ELSEVIER.2025: 631-632

- **Intra-leukemic interferon signaling suppresses expansion and mediates chemoresistance in human AML.** *Blood cancer discovery*

  Karigane, D., Fan, A. C., Nishimura, T., Kayamori, K., Nakauchi, Y., Köhnke, T., Rangavajhula, A., Ediriwickrema, A., Benard, B. A., Thomas, R., Zhao, F., Stafford, M., Suchy, et al

  2025

- **Multiple myeloma presenting with retroperitoneal fibrosis and elevated IgG4** *INTERNATIONAL JOURNAL OF HEMATOLOGY*

  Kayamori, K., Shono, K., Onoda, M., Yokota, A.

  2025

- **DNMT3AR882H Is Not Required for Disease Maintenance in Primary Human AML, but Is Associated With Increased Leukemia Stem Cell Frequency.** *bioRxiv : the preprint server for biology*

  Köhnke, T., Karigane, D., Hilgart, E., Fan, A. C., Kayamori, K., Miyauchi, M., Collins, C. T., Suchy, F. P., Rangavajhula, A., Feng, Y., Nakauchi, Y., Martinez-Montes, E., Fowler, et al

  2024

- **Lineage-tracing hematopoietic stem cell origins in vivo to efficiently make human HLF+ HOXA+ hematopoietic progenitors from pluripotent stem cells.** *Developmental cell*

  Fowler, J. L., Zheng, S. L., Nguyen, A., Chen, A., Xiong, X., Chai, T., Chen, J. Y., Karigane, D., Banuelos, A. M., Niizuma, K., Kayamori, K., Nishimura, T., Cromer, et al

  2024

- **Transposable Elements Are Differentially Expressed in MDS Stem Cells in a DiseaseStage-Specific Manner**
  Kurosawa, S., Oshima, M., Nakajima-Takagi, Y., Takayama, N., Shinoda, D., Kaito, S., Kamiya, T., Yamada, Y., Andoh, S., Kayamori, K., Sakaida, E., Sato, E., Yusa, et al
  AMER SOC HEMATOLOGY.2023

- **Preemptive Intervention in Airflow Obstruction Status Prevents the Development of Bronchiolitis Obliterans Syndrome after Allogeneic Stem Cell Transplantation: Multicenter, Prospective Phase II Study (Chiba AFO-01)**
  Tsukamoto, S., Kimura, K., Nakao, S., Takeda, Y., Ohwada, C., Shimizu, R., Nagao, Y., Shono, K., Onoda, M., Yokota, A., Arai, H., Utsu, Y., Masuda, et al
  AMER SOC HEMATOLOGY.2023

- **Intra-Leukemic IFN. Signaling Mediates Cell Cycle Suppression and Chemoresistance in AML**
  Karigane, D., Fan, A. C., Kayamori, K., Nakauchi, Y., Koehnke, T., Rangavajhula, A. S., Ediriwickrema, A., Majeti, R.
  AMER SOC HEMATOLOGY.2023

- **BCOR Loss Confers Increased Stemness and Partially Rescues RUNX1-Deficient Phenotypes in Human Hematopoietic Stem and Progenitor Cells**
  Jackson, K. K., Fan, A. C., Karigane, D., Zhao, F., Collins, C. T., Nakauchi, Y., Kayamori, K., Rangavajhula, A. S., Koehnke, T., Majeti, R.
  AMER SOC HEMATOLOGY.2023

- **Gene Correction of DNMT3A:R882H in Primary Human AML Demonstrates That This Mutation Is Not Required for Disease Maintenance, but Is Associated with Increased Leukemia Stem Cell Frequency**
  Koehnke, T., Karigane, D., Hilgart, E., Kayamori, K., Fan, A. C., Collins, C. T., Suchy, F. P., Rangavajhula, A. S., Feng, Y., Nakauchi, Y., Martinez-Montes, E., Koldobskiy, M., Feinberg, et al
  AMER SOC HEMATOLOGY.2023

- **Genome-wide CRISPR screening uncovers potential targets and mechanisms of vincristine resistance in DLBCL.** *British journal of haematology*
  He, M. Y., Kayamori, K.
  2023

- **Impact of standard-dose dipeptidyl peptidase-4 inhibitors on the incidence of graft-versus-host disease after allogeneic hematopoietic cell transplantation** *BONE MARROW TRANSPLANTATION*
  Kimura, S., Shimizu, H., Miyazaki, T., Sakurai, M., Tanoue, S., Kayamori, K., Ohwada, C., Yoshimura, K., Nakasone, H., Ohashi, T., Shono, K., Tachibana, T., Hatano, et al
  2022

- **Unraveling unique features of plasma cell clones in POEMS syndrome by single-cell analysis.** *JCI insight*
  Isshiki, Y., Oshima, M., Mimura, N., Kayamori, K., Miyamoto-Nagai, Y., Seki, M., Nakajima-Takagi, Y., Kanamori, T., Iwamoto, E., Muto, T., Tsukamoto, S., Takeda, Y., Ohwada, et al
  2022

- **Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia** *BLOOD ADVANCES*
  Wakita, S., Sakaguchi, M., Oh, I., Kako, S., Toya, T., Najima, Y., Doki, N., Kanda, J., Kuroda, J., Mori, S., Satake, A., Usuki, K., Ueki, et al
  2022; 6 (1): 238-247

- **DHODH inhibition synergizes with DNA-demethylating agents in the treatment of myelodysplastic syndromes** *BLOOD ADVANCES*
  Kayamori, K., Nagai, Y., Zhong, C., Kaito, S., Shinoda, D., Koide, S., Kuribayashi, W., Oshima, M., Nakajima-Takagi, Y., Yamashita, M., Mimura, N., Becker, H., Izawa, et al
  2021; 5 (2): 438-450

- **Efficacy of the novel tubulin polymerization inhibitor PTC-028 for myelodysplastic syndrome** *CANCER SCIENCE*
  Zhong, C., Kayamori, K., Koide, S., Shinoda, D., Oshima, M., Nakajima-Takagi, Y., Nagai, Y., Mimura, N., Sakaida, E., Yamazaki, S., Iwano, S., Miyawaki, A., Ito, et al
  2020; 111 (12): 4336-4347

- **Efficacy and tolerability of rituximab and reduced-dose cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy for elderly patient with diffuse large B-cell lymphoma** *HEMATOLOGY*
  Kayamori, K., Shono, K., Onoda, M., Yokota, A.
  2019; 24 (1): 52-59